Market Research Reports and Industry Reports

High-Grade Glioma - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
High-Grade Glioma - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 15, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
High-Grade Glioma - Overview 8
High-Grade Glioma - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
High-Grade Glioma - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
High-Grade Glioma - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Advenchen Laboratories LLC 27
AngioChem Inc 28
Arog Pharmaceuticals Inc 28
Astellas Pharma Inc 28
Athenex Inc 29
Bayer AG 29
Boehringer Ingelheim GmbH 30
Bristol-Myers Squibb Co 30
Cavion LLC 31
CBT Pharmaceuticals Inc 31
Celgene Corp 31
Concordia International Corp 32
DelMar Pharmaceuticals Inc 32
Eisai Co Ltd 33
Ipsen SA 33
Karyopharm Therapeutics Inc 34
Millennium Pharmaceuticals Inc 34
Nektar Therapeutics 34
Northwest Biotherapeutics Inc 35
Novartis AG 35
Ono Pharmaceutical Co Ltd 36
Sanofi 36
Sorrento Therapeutics Inc 37
Sumitomo Dainippon Pharma Co Ltd 37
Targepeutics Inc 38
Tocagen Inc 38
ZIOPHARM Oncology Inc 39
High-Grade Glioma - Drug Profiles 40
AdRTSIL-12 - Drug Profile 40
afatinib dimaleate - Drug Profile 49
alisertib - Drug Profile 63
apatinib mesylate - Drug Profile 69
bendamustine hydrochloride - Drug Profile 76
BMX-001 - Drug Profile 80
cabazitaxel - Drug Profile 82
CBT-101 - Drug Profile 84
Cellular Immunotherapy for High-Grade Glioma - Drug Profile 86
Cellular Immunotherapy for Oncology - Drug Profile 87
Cellular Immunotherapy for Oncology - Drug Profile 88
crenolanib besylate - Drug Profile 89
dabrafenib mesylate - Drug Profile 93
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 98
DCVax-L - Drug Profile 106
depatuxizumab mafodotin - Drug Profile 114
dianhydrogalactitol - Drug Profile 117
elatipepimut-S + adegrapepimut-S - Drug Profile 135
etirinotecan pegol - Drug Profile 137
flucytosine + TBio-01 - Drug Profile 144
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 145
GB-13 - Drug Profile 156
HSV-1716 - Drug Profile 157
ipilimumab + nivolumab - Drug Profile 161
irinotecan hydrochloride - Drug Profile 171
irinotecan hydrochloride + TBio-02 - Drug Profile 183
KX-02 - Drug Profile 185
lenvatinib mesylate - Drug Profile 187
mibefradil dihydrochloride - Drug Profile 206
nivolumab - Drug Profile 209
ONC-206 - Drug Profile 264
Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile 265
paclitaxel trevatide - Drug Profile 266
pomalidomide - Drug Profile 271
porfimer sodium - Drug Profile 278
RRX-001 - Drug Profile 280
selinexor - Drug Profile 282
sorafenib tosylate - Drug Profile 304
z-90099 - Drug Profile 313
High-Grade Glioma - Dormant Projects 314
High-Grade Glioma - Discontinued Products 315
High-Grade Glioma - Product Development Milestones 316
Featured News & Press Releases 316
Appendix 330
Methodology 330
Coverage 330
Secondary Research 330
Primary Research 330
Expert Panel Validation 330
Contact Us 330
Disclaimer 331

List Of Tables


Number of Products under Development for High-Grade Glioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
High-Grade Glioma - Pipeline by AbbVie Inc, H2 2017
High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2 2017
High-Grade Glioma - Pipeline by AngioChem Inc, H2 2017
High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H2 2017
High-Grade Glioma - Pipeline by Astellas Pharma Inc, H2 2017
High-Grade Glioma - Pipeline by Athenex Inc, H2 2017
High-Grade Glioma - Pipeline by Bayer AG, H2 2017
High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
High-Grade Glioma - Pipeline by Bristol-Myers Squibb Co, H2 2017
High-Grade Glioma - Pipeline by Cavion LLC, H2 2017
High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H2 2017
High-Grade Glioma - Pipeline by Celgene Corp, H2 2017
High-Grade Glioma - Pipeline by Concordia International Corp, H2 2017
High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
High-Grade Glioma - Pipeline by Eisai Co Ltd, H2 2017
High-Grade Glioma - Pipeline by Ipsen SA, H2 2017
High-Grade Glioma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
High-Grade Glioma - Pipeline by Nektar Therapeutics, H2 2017
High-Grade Glioma - Pipeline by Northwest Biotherapeutics Inc, H2 2017
High-Grade Glioma - Pipeline by Novartis AG, H2 2017
High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
High-Grade Glioma - Pipeline by Sanofi, H2 2017
High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H2 2017
High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
High-Grade Glioma - Pipeline by Targepeutics Inc, H2 2017
High-Grade Glioma - Pipeline by Tocagen Inc, H2 2017
High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H2 2017
High-Grade Glioma - Dormant Projects, H2 2017
High-Grade Glioma - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for High-Grade Glioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

High-Grade Glioma - Pipeline Review, H2 2017

High-Grade Glioma - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides an overview of the High-Grade Glioma

USD 2000View Report

High-Grade Glioma Global Clinical Trials Review, H2, 2017

High-Grade Glioma Global Clinical Trials Review, H2, 2017GlobalDatas clinical trial report, High-Grade Glioma Global Clinical Trials Review, H2, 2017 provides an overview of High-Grade Glioma clinical trials scenario. This report

USD 2500View Report

Recurrent Malignant Glioma - Pipeline Review, H2 2017

Recurrent Malignant Glioma - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Pipeline Review, H2 2017, provides an overview of the

USD 2000View Report

Pontine Glioma - Pipeline Review, H2 2017

Pontine Glioma - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H2 2017, provides an overview of the Pontine Glioma

USD 2000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2017
No. of Pages :333
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube